Bluebird Bio Inc. Stock

When initially glancing at the financials of bluebird bio (NASDAQ: BLUE), a company in the competitive Biotechnology & Medical Research industry, certain key figures immediately stand out. It's apparent that BLUE is in a challenging phase with a net income in the negative, indicating sustained losses over the analyzed periods. The consistent negative cash flow from operating activities suggests that the company's core operations are not yet profitable or self-sustaining. However, the company remains solvent with a notable amount of cash and short-term investments that ostensibly provide liquidity to fund ongoing research and development activities.

General Impressions of the Financials:

The broad financial health of bluebird bio raises some concerns, with the income statements highlighting a pattern of losses. Research and development expenses, common in the biotech sector where the development cycle is long and expensive, dominate their costs. Despite this, there are growth signals present, such as the reported quarterly revenue growth YOY (year over year), suggesting some progression in their operations.